A psychedelic could win FDA approval within months. None ever has.

As of today, no classic psychedelic — not psilocybin, MDMA, LSD, DMT, or ibogaine — is approved by the FDA for any indication [s3]. That sentence has been true for as long as the agency has existed. It may not be true much longer.

What the agency did

On April 24, 2026, the FDA issued National Priority Vouchers to three companies developing psychedelic-based therapies: Compass Pathways, for synthetic psilocybin in treatment-resistant depression; the Usona Institute, for psilocybin in major depressive disorder; and Transcend Therapeutics, for methylone, an MDMA-like compound, in PTSD [s1].

The vouchers compress the standard ten-to-twelve-month application review to one or two months [s1]. If the timelines hold, a first approval decision for a classic psychedelic therapy is plausible by late 2026 or early 2027 [s1].

A presidential executive order signed April 18, 2026 directs federal agencies to accelerate research, review, and approval of psychedelic drugs as treatments for serious mental health conditions [s1]. In July, the FDA opened a public hearing and comment period on considerations for future therapeutic use of psychedelic drugs [s2].

The MDMA exception

MDMA's path has been the least straightforward. In August 2024 the FDA declined to approve a New Drug Application and asked its sponsor to run another Phase 3 trial [s3].

The application was resubmitted this month by Resilient Pharmaceuticals, formerly Lykos — relying not on a new Phase 3 trial but on a third-party audit, a Phase 1 cardiac safety study, and follow-up data from the Department of Veterans Affairs [s3].

Whether that package satisfies the agency's original objection is the open question, and it is a meaningfully different question from the one facing psilocybin.

What compressed review does not compress

An accelerated review shortens the FDA's evaluation window. It does not shorten anything else, and the anything else is substantial.

These are not therapies that consist of taking a drug. The trials that generated the evidence paired dosing with structured psychological support across multi-hour supervised sessions. An approval creates immediate questions about who is qualified to provide that support, where it happens, how it is paid for, and what happens to the evidence base if the drug is delivered without the therapy that accompanied it in trials.

Compressed review also means less time to surface rare adverse events before a product reaches a population far larger and less carefully screened than any trial cohort.

The likely outcome of the next six months is a decision. What it will not be is a settled answer about how these treatments work in ordinary clinical practice.

This article is informational and is not medical advice.